Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.93 | N/A | -10.85% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.93 | N/A | -10.85% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding future performance. They highlighted ongoing challenges but did not provide specific metrics to address investor concerns.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges in the current market environment.
Crinetics Pharmaceuticals reported a wider-than-expected loss per share, which contributed to a 2.89% drop in stock price. The lack of revenue figures and guidance may have left investors uncertain about the company's future performance. Overall, the cautious tone from management suggests that challenges may persist in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AECOM
May 6, 2024